Chemotherapy choices by the surveyed physicians for the case scenarios presented

<p><b>Copyright information:</b></p><p>Taken from "Does / overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey"</p><p></p><p>Current Oncology 2006;13(1):2-7.</p><p>Published online Jan 2006</p><p>PMCID:PMC1891167.</p><p>2006 Multimed Inc.</p> All tumours were infiltrating ductal carcinoma: a) Age 47, 0.6 cm, grade 3, estrogen receptor negative (ER−), node-negative; b) age 59, 1.5 cm, grade 2, ER+, node-negative; c) age 65, 2.2 cm, grade 2, ER+, node-positive; d) age 43, 1.7 cm, grade 3, ER−, node-negative; e) age 37, grade 2, 1.1 cm, ER+, node-positive

Hormonal therapy choices by the surveyed physicians for estrogen receptor positive (ER+) scenarios

<p><b>Copyright information:</b></p><p>Taken from "Does / overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey"</p><p></p><p>Current Oncology 2006;13(1):2-7.</p><p>Published online Jan 2006</p><p>PMCID:PMC1891167.</p><p>2006 Multimed Inc.</p> All tumours were infiltrating ductal carcinoma: a) age 59; b) age 37